Compare Abbott Laboratories (ABT) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Iron Mountain Inc — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Iron Mountain Inc trades at $122.75 (market cap $36.19B). The key difference: Abbott Laboratories is far larger — about 5.2× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ABT | IRM | |
|---|---|---|
Market Cap | $187.95B | $36.19B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $133.06 |
52-Week Low | $82.57 | $78.86 |
Enterprise Value | $214.96B | $55.60B |
Dividend Yield | 2.32% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
